(Total Views: 455)
Posted On: 04/15/2021 12:03:07 AM
Post# of 36566
Note to Generex- possible patent infringement:
“Readers of this publication will note that a Pan-DR Epitope peptide (PADRE) was utilized in this antigen surface presentation design. However, we have decided to use the Ii-key technology instead of the PADRE approach to enhance the T helper response for the following reason. Both PADRE and Ii-key appear to reduce MHC Class II binding affinity variability due to genetic variation. However, Ii-key allows the use of pathogen-derived epitopes, and potent MHC Class II epitopes of SARS-CoV-2 have been identified. Including these viral epitopes in a vaccine design instead of a non-viral epitope will provide better T helper response to infection by a closely related virus (e.g. SARS-CoV-2 mutants), since T memory cells will be cross-reactive to the coronavirus epitopes, but not to the PADRE epitope.”
Put “Ii-key” as a term in “find on page”.
https://radvac.org/wp-content/uploads/2021/03....pdf#page6
“Readers of this publication will note that a Pan-DR Epitope peptide (PADRE) was utilized in this antigen surface presentation design. However, we have decided to use the Ii-key technology instead of the PADRE approach to enhance the T helper response for the following reason. Both PADRE and Ii-key appear to reduce MHC Class II binding affinity variability due to genetic variation. However, Ii-key allows the use of pathogen-derived epitopes, and potent MHC Class II epitopes of SARS-CoV-2 have been identified. Including these viral epitopes in a vaccine design instead of a non-viral epitope will provide better T helper response to infection by a closely related virus (e.g. SARS-CoV-2 mutants), since T memory cells will be cross-reactive to the coronavirus epitopes, but not to the PADRE epitope.”
Put “Ii-key” as a term in “find on page”.
https://radvac.org/wp-content/uploads/2021/03....pdf#page6
(1)
(0)
